While correlations between ANGs and VEGF‐C based on HER‐2 staus have been noted, understanding the clinical importance of this triple‐axis pathway is crucial for guiding future research into lymphatic diagnosis and treatments to prevent lymphoangiogenesis in breast cancer. This evidence concerns the gene VEGFC and breast cancer.